Which statement describes a feature of irritable bowel syndrome?
a. Abdominal discomfort is usually mild.
b. Effective treatment includes peppermint oil.
c. Constipation rather than diarrhea is the major adverse effect.
d. A combination of stress plus certain foods is needed to trigger an attack.
e. It is an autoimmune disease.
ANS: B
Q. 2A person with chronic diarrhea is at risk for which of the following?
a. Dehydration
b. Paradoxical constipation
c. Peptic ulcers
d. Heimlich's disease
e. GERD
Q. 3What is intestinal ischemia?
a. Reduced blood flow to the intestines
b. Chronic episodes of reverse peristalsis
c. Construction of intestinal lymph supply
d. Inflammation of two or more sphincter muscles
e. Severe and repeated episodes of intestinal blockage
Q. 4What substance controls the release of bile into the small intestine?
a. Gastrin
b. Secretin
c. Prozymogen
d. Cholecystokinin
e. Insulin
Q. 5Which action is associated with the presence of fat in the GI tract?
a. Inhibition of mucosal enzyme activities
b. Slowing of the process of digestion and absorption
c. Inhibition of thiamin, riboflavin, and niacin absorption
d. Stimulation and hastening of digestion and absorption
e. Markedly decreased transit time
Q. 6Which characteristic describes pancreatic digestive enzyme function?
a. The major hormone controlling the release of pancreatic enzymes is gastrin
b. The release of pancreatic enzymes is controlled primarily by a pancreatic sphincter
c. The pancreas can increase the activity of fat-degrading enzymes in response to more fat in the diet
d. In general, the amounts of digestive enzymes secreted by the pancreas remain constant over a wide range of nutrient intakes
e. Pancreatic enzymes can digest protein and fat but not carbohydrate
Q. 7Which substance stimulates the pancreas to release bicarbonate-rich juice?
a. Gastrin
b. Secretin
c. Glucagon
d. Gastric-inhibitory peptide
e. CCK
Q. 8The presence of fat in the intestines stimulates cells of the intestinal wall to release ____.
a. lipase
b. gastrin
c. secretin
d. cholecystokinin
e. glucagon